IOVAIovance Biotherapeutics, Inc.Signing up patients
A Study to Investigate the Safety and Efficacy of IOV-3001 in Adults With Advanced Melanoma Who Will Receive Lifileucel
Unresectable Melanoma · Metastatic Melanoma · Ocular Melanoma
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 1/2
- Patients
- 42 (planned)
- Started
- Mar 11, 2025
- Main results expected
- Jun 2032
- Fully finished
- Jul 2032
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Safety and Tolerability
Measured over: Up to 30 days
Recommended Dose for Phase 2
Measured over: Up to 30 days
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT06940739 · record last updated 2026-06-15 · checked 2026-11-09 15:47 UTC